neo_uterine
Table of Contents
uterine cancer
risk factors
- overall risk for all women is 3%
- genetic:
- FH increases risk
- hereditary nonpolyposis colon cancer (HNPCC or Lynch syndrome) have 70% chance of endometrial cancer
- most cases are caused by a defect in either the mismatch repair gene MLH1 or the gene MSH2
- at least 5 other genes can cause HNPCC: MLH3, MSH6, TGBR2, PMS1, and PMS2.
- mutations of the ARID1A and PIK3CA genes are frequently found together in the development of endometrial cancer, as well as in endometriosis-associated ovarian cancer
- ARID1A is a tumor suppressor. When it mutates, chromatin, cellular material that keeps DNA compacted in cells, loses its structure, allowing cancer to spread.
- PIK3CA is an instructional gene that tells the body to produce certain proteins and leads to uncontrolled growth of cells when it mutates.
- these same mutations often are found in women who have endometriosis but many of those affected never develop endometrial cancer suggesting additional factors are required to develop cancer
- obesity
- advancing age
- oestrogen-related issues:
- unopposed oestrogen therapy in menopause without progestogen (but taking combined increases risk of VTE and breast cancer)
- anti-oestrogens in menopause can cause endometrial hyperplasia and increase risk to 1% per annum
- combined oral contraceptive pill (OCP) reduces risk for 10 yrs after ceasing
- higher number of menstrual cycles over a lifetime increases risk
- early menarche before age 12yrs increases risk
- late menopause increases risk
- pregnancy reduces risk
- 3 pregnancies reduces risk by 50% compared to no pregnancies 1)
- certain ovarian tumours such as granulosa cell tumor which secretes high levels of oestrogen
- polycystic ovary syndrome (PCOS) 3-4x risk 2)
- iucd seems to lower risk
- diet - high fat diets are thought to be associated with increased risk
- lack of exercise
- type 2 diabetes appears to double risk but obesity and lack of exercise are confounding factors
- endometrial hyperplasia
- Simple atypical hyperplasia becomes cancer in 8% if untreated
- Complex atypical hyperplasia (CAH) becomes cancer in 29% if untreated
- pelvic radiotherapy
Ix for possible malignancy
- suspicious clinical pictures include:
- any post-menopausal bleeding
- clinically suggestive lesions such as cervical lesions, pelvic masses, enlarged uterus (although this may just be uterine fibroids (leiomyomas) or adenomyosis)
- intermenstrual bleeding
- post-coital bleeding
- endometrial hyperplasia - eg. the perimenopausal patient with a preceding period of amenorrhoea, or those on oestrogen only Rx.
- indications for uterine sampling3):
- women over 45 years age
- women with BMI > 30
- women with FH bowel cancer
- women with irregular bleeding
- abnormal endometrium on US
- NB. the chances of any endometrial pathology being present in a slim woman under age 45 years with regular menses is very small.
- indications of hysteroscopy4):
- suspected focal uterine pathology on US
- suboptimal US visualisation of the endometrium
- abnormal cavity seen on US
- no endometrial sample can be obtained through pipelle biopsy
Post Rx care
- short term vaginal oestrogen therapy < 2yrs appears to be safe for young endometrial cancer survivors5)
neo_uterine.txt · Last modified: 2026/03/04 21:29 by gary1